MCID: GNT002
MIFTS: 52

Giant Cell Glioblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Giant Cell Glioblastoma

MalaCards integrated aliases for Giant Cell Glioblastoma:

Name: Giant Cell Glioblastoma 12 59 55 15 72
Monstrocellular Sarcoma 12 72

Characteristics:

Orphanet epidemiological data:

59
giant cell glioblastoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3074
MeSH 44 D005909
NCIt 50 C4325
SNOMED-CT 68 44529004
ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 73 C0334588
Orphanet 59 ORPHA251579
UMLS 72 C0334588 C0334593

Summaries for Giant Cell Glioblastoma

Disease Ontology : 12 A glioblastoma multiforme that is characterized by a prevalence of bizarre, multinucleated giant cells.

MalaCards based summary : Giant Cell Glioblastoma, also known as monstrocellular sarcoma, is related to papilloma of choroid plexus and ganglioglioma, and has symptoms including seizures and headache. An important gene associated with Giant Cell Glioblastoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Trioxsalen and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and prostate, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 75 The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of... more...

Related Diseases for Giant Cell Glioblastoma

Diseases related to Giant Cell Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 papilloma of choroid plexus 30.2 TP53 SYP GFAP
2 ganglioglioma 30.0 TP53 SYP GFAP BRAF
3 pleomorphic xanthoastrocytoma 29.9 TP53 SYP MGMT IDH1 GFAP BRAF
4 gemistocytic astrocytoma 29.5 PTEN IDH2 GFAP
5 hydrocephalus 29.3 TP53 SYP PTEN GFAP FGFR3
6 glioblastoma multiforme 29.1 TP53 PTEN PPARG MGMT MDM2 IDH1
7 fibrillary astrocytoma 29.0 TP53 MGMT IDH2 IDH1 GFAP
8 glioblastoma 28.2 TP53 PTEN PPARG MGMT MDM2 IDH2
9 grade iii astrocytoma 28.0 TP53 PTEN MGMT MDM2 IDH2 GFAP
10 glioma 27.6 TP53 PTEN PPARG MDM2 IDH2 IDH1
11 brain cancer 26.8 TP53 SYP PTEN MGMT MDM2 IDH2
12 gliosarcoma 26.6 TP53 TACC3 TACC1 PTEN PPARG NFKBIA
13 plagiocephaly 10.7 FGFR3 FGFR1
14 nevus of ota 10.6 TP53 BRAF
15 brain ependymoma 10.6 TP53 EGFR
16 papillary tumor of the pineal region 10.6 SYP BRAF
17 desmoplastic infantile ganglioglioma 10.6 SYP GFAP
18 large cell carcinoma 10.5 SYP FGFR1 EGFR
19 pulmonary blastoma 10.5 TP53 SYP EGFR
20 basaloid squamous cell carcinoma 10.5 TP53 SYP EGFR
21 lung combined type small cell carcinoma 10.5 SYP GFAP
22 brain sarcoma 10.5
23 non-invasive bladder papillary urothelial neoplasm 10.5 TP53 FGFR3
24 cerebellar astrocytoma 10.5 TP53 IDH1
25 frontal convexity meningioma 10.5 TP53 GFAP
26 lung benign neoplasm 10.5 TP53 SYP EGFR
27 breast carcinoma in situ 10.4 TP53 FGFR1 EGFR
28 hyperplastic polyposis syndrome 10.4 TP53 BRAF
29 gliofibroma 10.4 TP53 GFAP
30 chiari malformation 10.4 SYP GFAP FGFR3
31 colorectal adenocarcinoma 10.4 TP53 EGFR BRAF
32 bladder squamous cell carcinoma 10.4 TP53 BRAF
33 extraventricular neurocytoma 10.4 SYP IDH1 GFAP
34 dysembryoplastic neuroepithelial tumor 10.3 SYP IDH1 GFAP
35 cellular ependymoma 10.3 TP53 SYP GFAP
36 angiocentric glioma 10.3 SYP IDH1 GFAP
37 zika virus infection 10.3 TP53 MDM2
38 pilocytic astrocytoma 10.3 IDH1 GFAP BRAF
39 central nervous system primitive neuroectodermal neoplasm 10.3 TP53 SYP GFAP
40 ring chromosome 7 10.3 TP53 MDM2
41 cerebral neuroblastoma 10.3 TP53 SYP GFAP
42 cerebral convexity meningioma 10.3 TP53 GFAP
43 cerebral ventricle cancer 10.3 TP53 SYP GFAP
44 cerebellopontine angle tumor 10.3 SYP IDH1 GFAP
45 lynch syndrome 10.3 TP53 MGMT EGFR BRAF
46 cystic teratoma 10.3 TP53 SYP GFAP
47 teratoma 10.3 TP53 SYP GFAP
48 cerebellar liponeurocytoma 10.3 TP53 SYP GFAP
49 ependymoma 10.3 SYP MGMT GFAP EGFR
50 central nervous system benign neoplasm 10.3 TP53 SYP GFAP

Graphical network of the top 20 diseases related to Giant Cell Glioblastoma:



Diseases related to Giant Cell Glioblastoma

Symptoms & Phenotypes for Giant Cell Glioblastoma

UMLS symptoms related to Giant Cell Glioblastoma:


seizures, headache

GenomeRNAi Phenotypes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.18 EGFR
2 Decreased viability GR00173-A 10.18 AURKB
3 Decreased viability GR00221-A-1 10.18 AURKB EGFR FGFR1 FGFR3 PPARG
4 Decreased viability GR00221-A-2 10.18 AURKB FGFR1 FGFR3 PPARG
5 Decreased viability GR00221-A-3 10.18 FGFR3 PPARG
6 Decreased viability GR00221-A-4 10.18 AURKB EGFR PPARG
7 Decreased viability GR00402-S-2 10.18 AURKB EGFR FGFR1 FGFR3 PPARG
8 Decreased viability in esophageal squamous lineage GR00235-A 9.7 AURKB BRAF BUB3 FGFR3 GFAP IDH1
9 Decreased substrate adherent cell growth GR00193-A-2 9.65 AURKB
10 Decreased substrate adherent cell growth GR00193-A-3 9.65 BRAF
11 Decreased substrate adherent cell growth GR00193-A-4 9.65 AURKB BRAF FGFR1
12 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.5 AURKB BRAF EGFR
13 Reduced mammosphere formation GR00396-S 9.17 BRAF BUB3 EGFR IDH2 MDM2 PPARG

MGI Mouse Phenotypes related to Giant Cell Glioblastoma:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 AURKB BRAF BUB3 EGFR FGFR1 FGFR3
2 growth/size/body region MP:0005378 10.43 AURKB BRAF BUB3 EGFR FGFR1 FGFR3
3 homeostasis/metabolism MP:0005376 10.43 AURKB BRAF BUB3 EGFR FGFR1 FGFR3
4 mortality/aging MP:0010768 10.4 AURKB BRAF BUB3 EGFR FGFR1 FGFR3
5 immune system MP:0005387 10.33 BRAF EGFR FGFR1 FGFR3 GFAP IDH1
6 cardiovascular system MP:0005385 10.32 AURKB BRAF EGFR FGFR1 GFAP IDH2
7 hematopoietic system MP:0005397 10.31 BRAF EGFR FGFR1 FGFR3 IDH1 MDM2
8 embryo MP:0005380 10.3 AURKB BRAF BUB3 EGFR FGFR1 MDM2
9 endocrine/exocrine gland MP:0005379 10.29 BRAF EGFR FGFR1 MDM2 MGMT NFKBIA
10 integument MP:0010771 10.28 AURKB BRAF BUB3 EGFR FGFR1 FGFR3
11 neoplasm MP:0002006 10.23 AURKB BRAF BUB3 EGFR FGFR3 IDH2
12 digestive/alimentary MP:0005381 10.21 BRAF EGFR FGFR1 FGFR3 GFAP MDM2
13 normal MP:0002873 10.18 BRAF EGFR FGFR1 FGFR3 GFAP MDM2
14 craniofacial MP:0005382 10.16 BRAF EGFR FGFR1 FGFR3 MDM2 TACC3
15 limbs/digits/tail MP:0005371 10.13 BRAF EGFR FGFR1 FGFR3 MDM2 PTEN
16 muscle MP:0005369 10.13 BRAF BUB3 EGFR FGFR1 GFAP MDM2
17 hearing/vestibular/ear MP:0005377 10.05 BRAF EGFR FGFR1 FGFR3 PPARG TP53
18 liver/biliary system MP:0005370 10.05 BRAF EGFR MDM2 PPARG PTEN TACC3
19 no phenotypic analysis MP:0003012 10.03 AURKB EGFR FGFR1 FGFR3 MDM2 MGMT
20 renal/urinary system MP:0005367 9.92 BRAF EGFR FGFR1 FGFR3 MDM2 PPARG
21 reproductive system MP:0005389 9.91 AURKB BRAF EGFR FGFR1 FGFR3 MDM2
22 pigmentation MP:0001186 9.77 BRAF EGFR MDM2 PTEN TP53
23 respiratory system MP:0005388 9.7 BRAF EGFR FGFR3 IDH1 MGMT PTEN
24 skeleton MP:0005390 9.7 BRAF BUB3 EGFR FGFR1 FGFR3 IDH1
25 vision/eye MP:0005391 9.28 BRAF BUB3 EGFR FGFR1 FGFR3 GFAP

Drugs & Therapeutics for Giant Cell Glioblastoma

Drugs for Giant Cell Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 3 3902-71-4 5585
2
Donepezil Approved Phase 3 120014-06-4 3152
3
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
4
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
5
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Analgesics Phase 3
13 Peripheral Nervous System Agents Phase 3
14 Antineoplastic Agents, Phytogenic Phase 3
15 Tubulin Modulators Phase 3
16 Antimitotic Agents Phase 3
17 Photosensitizing Agents Phase 3
18 Dihematoporphyrin Ether Phase 3
19 Central Nervous System Depressants Phase 3
20 Nootropic Agents Phase 3
21 Hematoporphyrin Derivative Phase 3
22 Hematoporphyrins Phase 3
23 Anesthetics Phase 3
24 Anesthetics, General Phase 3
25 Ether Phase 3
26 Anesthetics, Inhalation Phase 3
27 Cholinesterase Inhibitors Phase 3
28 Cholinergic Agents Phase 3
29 Liver Extracts Phase 3
30 Cola Phase 3
31 Anesthetics, Intravenous Phase 3
32 Narcotics Phase 3
33 Analgesics, Opioid Phase 3
34 Adjuvants, Anesthesia Phase 3
35 Gastrointestinal Agents Phase 3
36 Central Nervous System Stimulants Phase 3
37 Neurotransmitter Agents Phase 3
38 Dexmethylphenidate Hydrochloride Phase 3
39 Neurotransmitter Uptake Inhibitors Phase 3
40 Dopamine Uptake Inhibitors Phase 3
41 Dopamine Agents Phase 3
42 Anti-Allergic Agents Phase 3
43 Serotonin Antagonists Phase 3
44 Histamine H1 Antagonists Phase 3
45 Histamine Antagonists Phase 3
46 Serotonin Agents Phase 3
47
Histamine Phosphate Phase 3 51-74-1 65513
48 Antipruritics Phase 3
49
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
50
Ethanol Approved Phase 1, Phase 2 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 276)
# Name Status NCT ID Phase Drugs
1 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
3 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
4 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
5 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
6 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
7 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
8 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
9 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
10 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
11 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
12 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
17 Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
18 A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
19 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
20 A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
21 A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
22 Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups Unknown status NCT00313521 Phase 2 thiotepa
23 Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme Unknown status NCT01013285 Phase 2 temozolomide
24 Phase I/II Trial of Temozolomide and Carboplatin in Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
25 Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma Unknown status NCT00892177 Phase 2 dasatinib
26 A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma Completed NCT00459381 Phase 2 pazopanib hydrochloride
27 Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00268359 Phase 2 irinotecan hydrochloride
28 Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Completed NCT00423735 Phase 2 Dasatinib
29 Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
30 A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma Completed NCT00036660 Phase 2 SarCNU
31 A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme Completed NCT00016991 Phase 2 gefitinib
32 A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme Completed NCT00016328 Phase 2 temsirolimus
33 A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme Completed NCT00014677 Phase 2
34 Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme Completed NCT00014300 Phase 2 glufosfamide
35 A Phase II Trial of High Dose Tamoxifen For The Treatment of Newly Diagnosed Supratentorial Glioblastoma Multiforme (GBM) Completed NCT00006388 Phase 2 tamoxifen citrate
36 A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boosts For Supratentorial Glioblastoma Multiforme Completed NCT00006386 Phase 2 carmustine
37 Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme Completed NCT00006358 Phase 2 temozolomide;thalidomide
38 Phase II Trial of Intralesional Adoptive Cellular Therapy of Glioblastoma With Interleukin-2-Stimulated Lymphocytes Completed NCT00331526 Phase 2
39 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme Completed NCT00005826 Phase 2 rubitecan
40 Phase II Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent or Progressive Cerebral Anaplastic Gliomas Completed NCT00005081 Phase 2 O6-benzylguanine;carmustine
41 Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Patients With Glioblastoma Multiforme Completed NCT00004937 Phase 2 acridine carboxamide
42 A Randomized Double-Blind, Placebo-Controlled Phase II Study of the Matrix Metalloprotease Inhibitor Prinomastat in Combination With Temozolomide Following Radiation Therapy in Patients Having Newly Diagnosed Glioblastoma Multiforme Completed NCT00004200 Phase 2 prinomastat;temozolomide
43 Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme Completed NCT00004146 Phase 2 carboxyamidotriazole
44 A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma Completed NCT00004113 Phase 2 temozolomide
45 Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Completed NCT00004073 Phase 2 suramin
46 A Multi-Center, Open-Label Clinical Study to Evaluate the Safety and Performance of the Proxima GliaSite RTS, a Radiation Delivery System, in Patients With Recurrent Malignant Brain Tumors Undergoing Surgical Resection Completed NCT00003574 Phase 2
47 Phase II Treatment of Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme With Temodal Completed NCT00003464 Phase 2 temozolomide
48 Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting Completed NCT00047294 Phase 2 celecoxib;temozolomide;thalidomide
49 A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
50 ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS Completed NCT00002639 Phase 2 chemotherapy;suramin

Search NIH Clinical Center for Giant Cell Glioblastoma

Genetic Tests for Giant Cell Glioblastoma

Anatomical Context for Giant Cell Glioblastoma

MalaCards organs/tissues related to Giant Cell Glioblastoma:

41
Brain, T Cells, Prostate, Liver, Bone, Eye, Spinal Cord

Publications for Giant Cell Glioblastoma

Articles related to Giant Cell Glioblastoma:

(show top 50) (show all 121)
# Title Authors PMID Year
1
Genetic profile of the giant cell glioblastoma. 9 38
10068201 1999
2
p53 mutations versus EGF receptor expression in giant cell glioblastomas. 9 38
9370234 1997
3
Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma. 38
31009783 2019
4
Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma. 38
30368636 2019
5
Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. 38
30861589 2019
6
An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female. 38
31394931 2019
7
Imaging findings in the progression of a giant cell glioblastoma. 38
30128062 2018
8
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 38
30783357 2018
9
Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. 38
30279958 2018
10
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 38
30443141 2018
11
Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature. 38
29805603 2018
12
Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database. 38
28288541 2017
13
IDH-mutant giant cell glioblastoma: A neglected tumor variant? 38
29035191 2017
14
Giant Cell Glioblastoma in a Child with Clinical and Family History of Neurofibromatosis. 38
29114311 2017
15
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. 38
28261869 2017
16
Radiologic Dilemma in an Extra-Axial Petroclival Lesion: Low Grade versus High Grade. 38
28109858 2017
17
Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. 38
28161760 2017
18
Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. 38
26443480 2016
19
MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. 38
27253461 2016
20
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. 38
27013816 2016
21
Pediatric Giant Cell Glioblastoma Mimicking Hemorrhage Secondary to Ischemic Stroke. 38
26344331 2015
22
Giant cell glioblastoma with calcification and long-term survival. 38
26960525 2015
23
A spontaneously occurring malignant pituicytoma in a male sprague dawley rat. 38
26441479 2015
24
Adult classical glioblastoma with a BRAF V600E mutation. 38
25885250 2015
25
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients. 38
25037316 2014
26
Treatment and survival of patients harboring histological variants of glioblastoma. 38
24980627 2014
27
[Gliosarcoma of cerebral hemispheres: a clinicopathologic study of 10 cases]. 38
25567590 2014
28
Estimating the surface area of nonconvex particles from central planar sections. 38
24832486 2014
29
Cerebellar giant cell glioblastoma multiforme in an adult. 38
25002780 2014
30
BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. 38
24345274 2014
31
Giant-cell glioblastoma of childhood associated with HIV-1 and JC virus coinfection. 38
23702739 2013
32
Epithelioid GBMs show a high percentage of BRAF V600E mutation. 38
23552385 2013
33
Recurrent giant cell glioblastoma with the neuroradiologic picture of multiple meningiomas. 38
22241593 2013
34
Giant cell glioblastoma in the pediatric age group: Report of two cases. 38
23772243 2013
35
Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis Type 1. 38
22943956 2013
36
Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma. 38
22286149 2012
37
Giant cell glioblastoma in a child: A rare case report. 38
23293671 2012
38
Cytomorphology of giant cell glioblastoma: Report of a case and brief review of literature. 38
21319330 2012
39
Highly malignant behavior of a murine oligodendrocyte precursor cell line following transplantation into the demyelinated and nondemyelinated central nervous system. 38
22420305 2012
40
Glioblastoma multiforme in children: report of 13 cases and review of the literature. 38
21824566 2011
41
Acute tetraplegia and cardiac arrest following high cervical leptomeningeal metastasis of giant cell glioblastoma. 38
21658953 2011
42
Giant cell glioblastoma in the cerebrum of a Pembroke Welsh corgi. 38
21146179 2011
43
Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. 38
20051018 2010
44
A case of giant cell glioblastoma: a mimicker of a cerebral metastasis. 38
20973333 2010
45
Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. 38
20467329 2010
46
CD34 expression in glioblastoma and giant cell glioblastoma. 38
20175958 2010
47
Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. 38
19332771 2009
48
Long-Term Survival of a Patient with Giant Cell Glioblastoma: Case Report and Review of the Literature. 38
20740171 2009
49
Pediatric giant cell glioblastoma: New insights into a rare tumor entity. 38
19050301 2009
50
Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex. 38
18673443 2009

Variations for Giant Cell Glioblastoma

Expression for Giant Cell Glioblastoma

Search GEO for disease gene expression data for Giant Cell Glioblastoma.

Pathways for Giant Cell Glioblastoma

Pathways related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 TP53 PTEN NFKBIA MDM2 GFAP FGFR3
2
Show member pathways
13.01 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
3
Show member pathways
12.96 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
4
Show member pathways
12.83 PTEN NFKBIA FGFR3 FGFR1 EGFR BRAF
5
Show member pathways
12.78 TP53 PTEN PPARG NFKBIA MDM2 FGFR1
6 12.73 TP53 FGFR3 FGFR1 EGFR BRAF
7
Show member pathways
12.72 TP53 PTEN FGFR1 EGFR BRAF
8
Show member pathways
12.65 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
9
Show member pathways
12.64 TP53 PTEN NFKBIA MDM2 FGFR3 FGFR1
10 12.53 TP53 PTEN PPARG NFKBIA MDM2 FGFR3
11 12.49 TP53 PTEN MDM2 FGFR3 EGFR
12 12.48 TP53 TACC3 MGMT MDM2 BUB3 AURKB
13
Show member pathways
12.47 TP53 PTEN FGFR3 FGFR1 EGFR BRAF
14
Show member pathways
12.39 TP53 NFKBIA MDM2 FGFR3 FGFR1 EGFR
15
Show member pathways
12.35 TP53 PTEN NFKBIA MDM2
16 12.27 TP53 MDM2 FGFR1 EGFR BRAF
17
Show member pathways
12.21 TP53 PPARG NFKBIA BRAF
18
Show member pathways
12.19 PTEN FGFR3 FGFR1 EGFR
19 12.13 TP53 PTEN MDM2 EGFR BRAF
20
Show member pathways
12.05 PTEN MDM2 EGFR BRAF
21
Show member pathways
12.05 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
22 12.04 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
23 12.03 TP53 PTEN MDM2 EGFR
24
Show member pathways
11.99 TP53 NFKBIA EGFR BRAF
25 11.91 TP53 PTEN MDM2 BRAF
26 11.82 TP53 PTEN NFKBIA
27 11.81 PTEN MDM2 EGFR
28
Show member pathways
11.79 TP53 NFKBIA MDM2
29 11.78 TP53 PTEN MGMT MDM2 EGFR BRAF
30 11.77 SYP GFAP FGFR3 FGFR1
31 11.63 TP53 MDM2 FGFR3 EGFR BRAF
32
Show member pathways
11.56 TP53 NFKBIA MDM2
33 11.55 TP53 PTEN MDM2
34 11.47 TP53 PTEN MDM2
35 11.46 FGFR3 FGFR1 EGFR
36 11.44 TP53 NFKBIA MDM2
37 11.41 FGFR3 FGFR1 EGFR BRAF
38 11.36 FGFR3 FGFR1 EGFR BRAF
39 11.27 TP53 PTEN IDH1 FGFR3 FGFR1 EGFR
40
Show member pathways
10.8 IDH2 IDH1
41 10.59 TP53 TACC3 TACC1 NFKBIA MDM2 AURKB

GO Terms for Giant Cell Glioblastoma

Cellular components related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 TP53 TACC3 TACC1 PTEN PPARG NFKBIA
2 cytosol GO:0005829 9.44 TP53 TACC3 PTEN PPARG NFKBIA MDM2

Biological processes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 protein deubiquitination GO:0016579 9.92 TP53 PTEN NFKBIA MDM2
2 MAPK cascade GO:0000165 9.88 FGFR3 FGFR1 EGFR BRAF
3 peptidyl-tyrosine phosphorylation GO:0018108 9.8 FGFR3 FGFR1 EGFR BRAF
4 regulation of cell proliferation GO:0042127 9.78 NFKBIA FGFR1 EGFR BRAF
5 regulation of signal transduction by p53 class mediator GO:1901796 9.77 TP53 MDM2 AURKB
6 protein autophosphorylation GO:0046777 9.76 FGFR3 FGFR1 EGFR AURKB
7 cellular response to drug GO:0035690 9.71 TP53 EGFR BRAF
8 cell proliferation GO:0008283 9.63 TP53 TACC3 TACC1 PTEN EGFR AURKB
9 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.62 PPARG NFKBIA
10 regulation of chromosome segregation GO:0051983 9.61 BUB3 AURKB
11 protein localization to kinetochore GO:0034501 9.61 BUB3 AURKB
12 negative regulation of telomerase activity GO:0051974 9.6 TP53 PPARG
13 salivary gland morphogenesis GO:0007435 9.58 FGFR1 EGFR
14 long-term synaptic potentiation GO:0060291 9.58 PTEN GFAP BRAF
15 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.57 TP53 EGFR
16 NADP metabolic process GO:0006739 9.56 IDH2 IDH1
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.56 PTEN FGFR3 EGFR BRAF
18 attachment of spindle microtubules to kinetochore GO:0008608 9.55 BUB3 AURKB
19 positive regulation of phospholipase activity GO:0010518 9.52 FGFR3 FGFR1
20 regulation of axon regeneration GO:0048679 9.51 PTEN BRAF
21 isocitrate metabolic process GO:0006102 9.43 IDH2 IDH1
22 cellular response to actinomycin D GO:0072717 9.37 TP53 MDM2
23 response to organic cyclic compound GO:0014070 9.35 PTEN PPARG MGMT IDH1 EGFR
24 glyoxylate cycle GO:0006097 9.32 IDH2 IDH1
25 negative regulation of apoptotic process GO:0043066 9.17 TP53 PTEN NFKBIA MGMT MDM2 EGFR
26 positive regulation of cell proliferation GO:0008284 10.03 PTEN MDM2 FGFR3 FGFR1 EGFR

Molecular functions related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.89 FGFR3 FGFR1 EGFR BRAF AURKB
2 nucleotide binding GO:0000166 9.85 FGFR3 FGFR1 EGFR BRAF AURKB
3 protein tyrosine kinase activity GO:0004713 9.67 FGFR3 FGFR1 EGFR BRAF
4 protein phosphatase binding GO:0019903 9.65 TP53 PPARG EGFR
5 protein self-association GO:0043621 9.61 TP53 SYP PPARG
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 FGFR3 FGFR1 EGFR
7 enzyme binding GO:0019899 9.43 TP53 PTEN PPARG NFKBIA MDM2 EGFR
8 identical protein binding GO:0042802 9.4 TP53 SYP PTEN PPARG NFKBIA MDM2
9 fibroblast growth factor-activated receptor activity GO:0005007 9.32 FGFR3 FGFR1
10 isocitrate dehydrogenase activity GO:0004448 9.26 IDH2 IDH1
11 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH2 IDH1

Sources for Giant Cell Glioblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....